SG10201902915VA - Polysaccharide and nucleic acid formulations containing viscosity-lowering agents - Google Patents

Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Info

Publication number
SG10201902915VA
SG10201902915VA SG10201902915VA SG10201902915VA SG10201902915VA SG 10201902915V A SG10201902915V A SG 10201902915VA SG 10201902915V A SG10201902915V A SG 10201902915VA SG 10201902915V A SG10201902915V A SG 10201902915VA SG 10201902915V A SG10201902915V A SG 10201902915VA
Authority
SG
Singapore
Prior art keywords
lowering agents
polysaccharide
nucleic acid
viscosity
formulations containing
Prior art date
Application number
SG10201902915VA
Other languages
English (en)
Inventor
Alyssa Larson
Kevin Love
Alisha Weight
Alan Crane
Robert Langer
Alexander Klibanov
Original Assignee
Eagle Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Biologics Inc filed Critical Eagle Biologics Inc
Publication of SG10201902915VA publication Critical patent/SG10201902915VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201902915VA 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents SG10201902915VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462058125P 2014-10-01 2014-10-01
US201462058122P 2014-10-01 2014-10-01
US201462058124P 2014-10-01 2014-10-01
US201462058123P 2014-10-01 2014-10-01

Publications (1)

Publication Number Publication Date
SG10201902915VA true SG10201902915VA (en) 2019-04-29

Family

ID=55631454

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201702614SA SG11201702614SA (en) 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
SG10201902915VA SG10201902915VA (en) 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201702614SA SG11201702614SA (en) 2014-10-01 2015-09-30 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Country Status (11)

Country Link
US (1) US11471479B2 (ja)
EP (1) EP3200804A4 (ja)
JP (1) JP6716577B2 (ja)
KR (1) KR102497368B1 (ja)
CN (1) CN106999510B (ja)
AU (1) AU2015325055B2 (ja)
CA (1) CA2962768C (ja)
IL (1) IL251390B (ja)
MX (1) MX2017004306A (ja)
SG (2) SG11201702614SA (ja)
WO (1) WO2016054259A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808338A1 (en) * 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
RU2612014C1 (ru) * 2015-10-19 2017-03-01 Общество с ограниченной ответственностью "ДИАМЕД-фарма" Средство для лечения артрологических заболеваний
KR102572453B1 (ko) * 2017-02-16 2023-08-29 코메라 라이프 사이언시스, 인코포레이티드 단백질 가공 처리를 위한 부형제 화합물
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
KR102101384B1 (ko) * 2017-11-02 2020-04-16 연세대학교 산학협력단 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물
JP7425726B2 (ja) * 2017-11-17 2024-01-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
KR102056144B1 (ko) * 2018-03-08 2019-12-16 주식회사 파마리서치프로덕트 Dna 단편 혼합물이 고농도로 함유된 유동성을 갖는 액제 조성물 및 이의 제조방법
US11655210B2 (en) 2018-05-18 2023-05-23 The General Hospital Corporation Compound for improving L-arginine bioavailability
US11365405B2 (en) 2019-03-20 2022-06-21 Anchor Molecular Inc. Method of removing nucleic acids from human plasma
WO2020212628A1 (es) * 2019-04-18 2020-10-22 Fundació Institut De Ciències Fotòniques Aparato fluídico para interrogación óptica de microorganismos individuales
WO2021097228A1 (en) * 2019-11-13 2021-05-20 The General Hospital Corporation Compositions and salts for improving l-arginine bioavailability
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
CN112458001B (zh) * 2020-07-30 2022-09-27 上海交通大学 一种可降解多环芳烃的菌株及其应用
US20240024093A1 (en) * 2022-07-22 2024-01-25 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use
WO2024028218A1 (en) * 2022-08-01 2024-02-08 Merck Patent Gmbh Viscosity reducing excipients and combinations thereof for highly concentrated nucleic acid compositions
WO2024089094A1 (en) * 2022-10-26 2024-05-02 Dsm Ip Assets B.V. Preparation and compositions comprising saccharides and amino acids, and use thereof

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750373A (en) 1953-01-15 1956-06-13 Pfizer & Co C Improvements in or relating to injectable suspension of penicillin salts
DK128416B (da) 1964-08-13 1974-04-29 Ciba Geigy Ag Analogifremgangsmåde til fremstilling af adrenocorticotropt aktive nonadecapeptidamider eller syreadditionssalte eller kompleksforbindelser deraf.
BE757195A (fr) 1969-10-07 1971-03-16 Century Disposable Devices Seringue servant a injecter un melange fraichement prepare de poudre etde liquide
JPS5270014A (en) 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
US4171698A (en) 1977-08-15 1979-10-23 Abbott Laboratories Prefilled two-compartment syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
ATE171185T1 (de) 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5001000A (en) 1988-09-26 1991-03-19 E. I. Du Pont De Nemours And Company Process for forming a composite structure of thermoplastic polymer and sheet molding compound
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
JPH03190823A (ja) 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd エリスロポエチン皮下又は筋肉投与剤
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
US5334162A (en) 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3524974B2 (ja) 1994-12-26 2004-05-10 ブラッコ インターナショナル ビーヴィ プレフィルドシリンジおよびその包装体
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5819998A (en) 1996-09-30 1998-10-13 Everything Kids Knapsack with simulated basketball court
IN184589B (ja) 1996-10-16 2000-09-09 Alza Corp
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999018994A1 (fr) 1997-10-15 1999-04-22 Asahi Kasei Kogyo Kabushiki Kaisha Procede pour conserver la qualite d'une solution parenterale aqueuse de thrombomoduline pour l'entreposage ou la distribution
DE69837399T2 (de) 1997-10-22 2007-12-20 Chugai Seiyaku K.K. Verfahren zum screening von tgf-beta inhibierenden substanzen
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
FR2794649B1 (fr) * 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
AUPQ132599A0 (en) * 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
EP1072323B1 (de) 1999-07-29 2003-09-10 Wilhelm A. Keller Kartuschen-Austraggerät mit Antrieb für dynamischen Mischer
AU783306B2 (en) 1999-10-04 2005-10-13 Novartis Vaccines And Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
CA2430499C (en) 2000-11-30 2012-05-22 Biovalve Technologies, Inc. Injection systems
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
CA2446127A1 (en) 2001-05-16 2002-11-21 Biomarin Pharmaceutical Inc. Destruction of prions using vibriolysin or variants thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
WO2003011782A2 (en) 2001-08-02 2003-02-13 3M Innovative Properties Company Alumina-zirconia, and methods of making and using the same
JP4167820B2 (ja) 2001-10-19 2008-10-22 アルインコ株式会社 デッキプレート走行台車
GB0212405D0 (en) 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
ES2335005T5 (es) 2003-03-05 2013-04-17 Halozyme, Inc. Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
CA2520775A1 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US7341843B2 (en) 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
WO2004092361A1 (en) 2003-04-15 2004-10-28 Ista Pharmaceuticals, Inc. Process for isolating and purifing ovine hyaluronidase
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
WO2005000345A2 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
CN1206344C (zh) * 2003-07-28 2005-06-15 中国海洋大学 一种用细菌生产岩藻聚糖硫酸酯酶的方法
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
ES2346212T3 (es) 2004-11-25 2010-10-13 Chr. Hansen A/S Metodo para la preparacion de una laca de acido carminico.
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US8232265B2 (en) 2005-10-07 2012-07-31 Board Of Trustees Of The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
CN100416002C (zh) 2005-10-26 2008-09-03 曲新华 污水再生利用装置
PL1962886T6 (pl) 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
ITMI20061030A1 (it) * 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
CU23526B6 (es) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
KR20150028856A (ko) 2007-05-31 2015-03-16 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
WO2009015367A2 (en) 2007-07-25 2009-01-29 Arizona Board Of Regents For And On Behalf Of Arizona State University Stabilizing proteins using ionic liquids
AU2008289225A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and Fc-fusion molecules using polycations
WO2009043049A2 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
CN101861335B (zh) * 2007-10-16 2013-09-04 环状药物公司 凝血因子viia调节剂的制造、组合物和用途
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
WO2009086062A1 (en) 2007-12-21 2009-07-09 Lyotropic Therapeutics, Inc. Stabilized formulations of peptides and proteins
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009137471A2 (en) 2008-05-05 2009-11-12 University Of Miami Azo dye related small molecule modulators of protein-protein interactions
EP2123307A1 (en) 2008-05-20 2009-11-25 Hexal Ag Method for reducing leachables and extractables in syringes
WO2010056657A2 (en) * 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
TWI342781B (en) 2008-12-01 2011-06-01 Univ China Medical Blood sugar-modulating polypeptides
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
WO2010132047A1 (en) 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
KR101882408B1 (ko) 2009-05-20 2018-07-27 세키스이 메디칼 가부시키가이샤 혈액응고시간 연장제
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
AU2010279569A1 (en) 2009-08-04 2012-03-01 Genentech, Inc. Concentrated polypeptide formulations with reduced viscosity
JP5734985B2 (ja) 2009-09-17 2015-06-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
US8895242B2 (en) 2009-10-20 2014-11-25 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2010320515B2 (en) 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
US9289381B2 (en) 2009-12-03 2016-03-22 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
AU2010327998B2 (en) 2009-12-10 2015-11-12 Iowa State University Research Foundation, Inc. TAL effector-mediated DNA modification
ES2522935T3 (es) 2010-01-08 2014-11-19 Chanel Parfums Beauté Uso de al menos un extracto de flores de Camellia japonica alba plena para hidratar la piel
CA2788863C (en) 2010-02-04 2020-07-07 Reinhard Franz Bolli Immunoglobulin preparation
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物
US20130028920A1 (en) 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
CN101851267A (zh) 2010-04-22 2010-10-06 江南大学 一种抗体保护剂及其应用
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
GB201012179D0 (en) 2010-07-20 2010-09-01 Future Injection Technologies Injection device
US8936827B2 (en) * 2011-02-25 2015-01-20 Abbott Cardiovascular Systems Inc. Methods of loading a hollow stent with a drug or drug formulation
CA2832556A1 (en) 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
CA2832560A1 (en) 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
WO2012155035A1 (en) * 2011-05-12 2012-11-15 Medrad, Inc. Fluid injection system having various systems for controlling an injection procedure
RU2485133C2 (ru) 2011-05-30 2013-06-20 Закрытое Акционерное Общество "Фарм-Синтез" Белково-полипептидный комплекс, обладающий тканеспецифическим регенеративно-репаративным и омолаживающим действием на кожную ткань, способ его получения и фармацевтическая композиция на его основе
WO2013063290A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3578203A1 (en) 2011-10-28 2019-12-11 Integritybio Inc. Protein formulations containing amino acids
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
WO2013112986A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
US20160002624A1 (en) * 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) * 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
MY188825A (en) 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
RU2014152803A (ru) 2012-05-25 2016-07-20 Новартис Аг Водная фармацевтическая композиция, содержащая терапевтический агент и гуанидин, производное гуанидина, и инъекция, включающая эту композицию
DK2800811T3 (en) 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
WO2013190047A1 (en) 2012-06-21 2013-12-27 Ucb Pharma S.A. Pharmaceutical formulation
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
CN104704001B (zh) 2012-08-09 2019-02-12 罗切格利卡特公司 Asgpr抗体及其用途
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
WO2014160083A1 (en) * 2013-03-13 2014-10-02 Applied Cardiovascular Solutions, Llc. Methods, compositions, and devices for the occlusion of cavities and passageways
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
EP3808338A1 (en) 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Also Published As

Publication number Publication date
AU2015325055B2 (en) 2021-02-25
CA2962768A1 (en) 2016-04-07
IL251390A0 (en) 2017-05-29
IL251390B (en) 2022-01-01
CA2962768C (en) 2023-10-10
JP6716577B2 (ja) 2020-07-01
EP3200804A4 (en) 2018-04-18
US11471479B2 (en) 2022-10-18
SG11201702614SA (en) 2017-04-27
KR102497368B1 (ko) 2023-02-10
US20180228831A1 (en) 2018-08-16
JP2017530196A (ja) 2017-10-12
EP3200804A1 (en) 2017-08-09
MX2017004306A (es) 2017-12-20
KR20170078669A (ko) 2017-07-07
WO2016054259A1 (en) 2016-04-07
CN106999510B (zh) 2021-04-30
CN106999510A (zh) 2017-08-01
AU2015325055A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
IL263670A (en) Assemblies and methods for infusion pump system delivery kits
MX2016005252A (es) Sistema de infusion para prevenir el uso del canal equivocado para la administracion de multiples medicamentos.
EP4309643A3 (en) Viscosity-reducing excipient compounds for protein formulations
WO2015095624A3 (en) Drug mixing and delivery system and method
BR112018008017A2 (pt) composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção
EP3659650A4 (en) PISTON ARRANGEMENT, MEDICAL SOLUTION DOSING DEVICE AND DRIVE METHOD OF THE PISTON ARRANGEMENT
EP3275482A4 (en) Syringe holder and medical solution administration set
WO2015034870A3 (en) Double-chamber mixing syringe and method of use
NZ728401A (en) High purity oritavancin and method of producing same
EP3727497A4 (en) INFUSION PUMP SYSTEMS AND METHODS FOR ADMINISTRATION SETS
HK1256027A1 (zh) 用於以輸注或注射形式進行靜脈給藥的左西孟旦以及輸注濃縮液的改善配方
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
EP3777924A4 (en) PRE-FILLED SYRINGE, LIQUID MEDICATION DELIVERY SYSTEM AND SYRINGE PUMP
MX2017008000A (es) Sistema de inyeccion de un solo uso.
EP3305347A4 (en) LIQUID INFUSION DEVICE FOR MEDICINE ADMINISTRATION TO A PATIENT
EP3231432A4 (en) Agent for hypodermic injections and production method for syringes containing agent for hypodermic injections
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
MX2016009458A (es) Solucion alcoholica estable de alprostadilo.
PH12017501005A1 (en) Injectable formulations of paracetamol
AU2016902092A0 (en) iChamber - innovative fluid delivery system to be used in multiple fields of medicine.
AU2015902834A0 (en) A syringe plunger for used ampule retention for administered drug identification purposes
WO2016100523A3 (en) Triphasic dosing regimens for the administration of time-dependent antibiotics and devices for the same